{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:23Z","timestamp":1786982363705,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Clinical Research Found of Tokyo Metropolitan Government","award":["H290303015"],"award-info":[{"award-number":["H290303015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12282-020-01049-4","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T13:03:12Z","timestamp":1578920592000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-3209","authenticated-orcid":false,"given":"Risa","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"5","key":"1049_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717\u201334.","journal-title":"Nat Rev Clin Oncol."},{"key":"1049_CR4","doi-asserted-by":"crossref","unstructured":"Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010; 11(1):7\u201313","DOI":"10.1038\/ni.1818"},{"issue":"11","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1084\/jem.193.11.1295","volume":"193","author":"MK Levings","year":"2001","unstructured":"Levings MK, Sangregorio R, Human RMG. cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded invitro without loss of function. J Exp Med. 2001;193(11):1295\u2013302.","journal-title":"J Exp Med"},{"issue":"9","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood.V98.9.2736","volume":"98","author":"WF Ng","year":"2001","unstructured":"Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98(9):2736\u201344.","journal-title":"Blood"},{"issue":"6","key":"1049_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri821","volume":"2","author":"EM Shevach","year":"2002","unstructured":"Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2(6):389\u2013400.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nri1026","volume":"3","author":"JF Bach","year":"2003","unstructured":"Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3(3):189\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/nri1488","volume":"4","author":"PJ Coffer","year":"2004","unstructured":"Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4(11):889\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"5609","key":"1049_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Sci (N Y). 2003;299(5609):1057\u201361.","journal-title":"Sci (N Y)"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","volume":"212","author":"S Sakaguchi","year":"2006","unstructured":"Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8\u201327.","journal-title":"Immunol Rev"},{"issue":"11","key":"1049_CR12","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-11-3216","volume":"18","author":"RJ deLeeuw","year":"2012","unstructured":"deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345\u201352.","journal-title":"Nat Immunol"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1186\/s12885-015-1742-7","volume":"15","author":"D Jiang","year":"2015","unstructured":"Jiang D, Gao Z, Cai Z, Wang M, He J. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15:727.","journal-title":"BMC Cancer"},{"issue":"36","key":"1049_CR15","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1200\/JCO.2011.35.0165","volume":"29","author":"AM Nichol","year":"2011","unstructured":"Nichol AM, Yerushalmi R, Tyldesley S, Lesperance M, Bajdik CD, Speers C, et al. A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol. 2011;29(36):4763\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1049_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-006-9455-x","volume":"105","author":"HM Verkooijen","year":"2007","unstructured":"Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007;105(3):347\u201357.","journal-title":"Breast Cancer Res Treat"},{"key":"1049_CR17","doi-asserted-by":"crossref","unstructured":"Kurebayashi J, Miyosi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22(3):235\u201344.","DOI":"10.1007\/s12282-015-0599-6"},{"key":"1049_CR18","unstructured":"Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer, the 17 Kanehara & Co. Ltd, Tokyo; 2012."},{"issue":"31","key":"1049_CR19","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"key":"1049_CR20","first-page":"273","volume":"22","author":"T Aruga","year":"2009","unstructured":"Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Kitagawa D, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009;22:273\u20138.","journal-title":"Oncol Rep"},{"issue":"3","key":"1049_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl."},{"key":"1049_CR22","doi-asserted-by":"crossref","unstructured":"Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9(9):XC05\u20138.","DOI":"10.7860\/JCDR\/2015\/14880.6511"},{"issue":"2","key":"1049_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-009-0718-1","volume":"120","author":"DM Renz","year":"2010","unstructured":"Renz DM, B\u00f6ttcher J, Baltzer PA, Dietzel M, Vag T, Gajda M, et al. The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer. Breast Cancer Res Treat. 2010;120(2):449\u201359.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12032-013-0711-8","volume":"30","author":"B Baker","year":"2013","unstructured":"Baker B, Morcos B, Daoud F, Sughayer M, Shabani H, Salameh H, et al. Histo-biological comparative analysis of bilateral breast cancer. Med Oncol. 2013;30(4):711.","journal-title":"Med Oncol"},{"issue":"2","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","volume":"130","author":"F Liu","year":"2011","unstructured":"Liu F, Lang R, Zhao J, Zhang X, Fan Y, et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645\u201355.","journal-title":"Breast Cancer Res Treat"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/onc.2010.174","volume":"29","author":"F Martin","year":"2010","unstructured":"Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli G. Human FOXP3 and cancer. Oncogene. 2010;29:4121\u20139.","journal-title":"Oncogene"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01049-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-020-01049-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01049-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T17:07:42Z","timestamp":1610471262000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-020-01049-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01049-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"21 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Showa University Hospital (approval number #1969), and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number #1638).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants comprehensively provided their consent stating that the tissue samples from resected specimen may be used for various researches. The ethics committee of Showa University Hospital (approval number #1969), and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number #1638) approved the authors\u2019 request for waiver of informed consent based on ethical consideration. All patients have the option to confirm ongoing studies on Showa University and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital web sites and may choose to opt out of consent at any time. The ethics committee approved this consent procedure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}